Jackson J Wallner, Ingrid A Beck, Nuttada Panpradist, Parker S Ruth, Humberto Valenzuela-Ponce, Maribel Soto-Nava, Santiago Ávila-Ríos, Barry R Lutz, Lisa M Frenkel
Article in AIDS research and human retroviruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 3 institutions in 2 countries.
Jackson J WallnerCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.ORCID 0000-0001-8438-511X
Ingrid A BeckCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Nuttada PanpradistDepartment of Bioengineering, University of Washington, Seattle, Washington, USA.
Parker S RuthDepartment of Bioengineering, University of Washington, Seattle, Washington, USA.
Humberto Valenzuela-PonceCIENI Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases (INER), Mexico City, Mexico.
Maribel Soto-NavaCIENI Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases (INER), Mexico City, Mexico.
Santiago Ávila-RíosCIENI Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases (INER), Mexico City, Mexico.
Barry R LutzDepartment of Bioengineering, University of Washington, Seattle, Washington, USA.
Lisa M FrenkelCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.ORCID 0000-0001-9566-8959
Infectious Disease Research Institute · USNational Institute of Cardiovascular Diseases · BDUniversity of Washington · US
Funding
LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
V-OLA: point-of-care HIV viral load monitoring and drug resistance testingR01AI145486 · NIAID · UNIVERSITY OF WASHINGTON · PI Barry Ryan Lutz · 2019 to 2026
$5.6M
A rapid point-of-treatment diagnostic assay for HIV-resistance to 1st-line ARTR01AI110375 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI FRENKEL, LISA M · 2014 to 2018
The nucleoside reverse transcriptase inhibitor abacavir (ABC) is used commonly to treat young children with HIV infection and is a component of the fixed-dose-combination Triumeq
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Rapid Near Point-of-Care Assay for · full record | OpenQuestion